Company Description

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.

The company is based in Irvine, California.

AEON Biopharma, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	10
CEO	Marc Forth

Contact Details

Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States
Phone	(949) 354-6499
Website	aeonbiopharma.com

Stock Details

Ticker Symbol	AEON
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001837607
CUSIP Number	00775E102
ISIN Number	US00791X1000
Employer ID	85-3940478
SIC Code	2834

Key Executives

Name	Position
Marc Forth	President, Chief Executive Officer and Director
Dr. Chad K. Oh M.D.	Chief Medical Officer
Peter A. Reynolds CPA	Chief Financial Officer
Alex Wilson	Executive Vice President, Chief Legal Officer and Corporate Secretary

Latest SEC Filings

Date	Type	Title
Jul 9, 2024	8-K	Current Report
Jun 14, 2024	8-K	Current Report
May 31, 2024	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
May 16, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 14, 2024	ARS/A	Filing
May 14, 2024	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 14, 2024	10-K/A	[Amend] Annual report
May 3, 2024	8-K	Current Report

View All SEC Filings